Meeting
2019 ASCO Annual Meeting
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study.
Presenter
Brian I. Rini, MD, FACP
Cleveland Clinic Taussig Cancer Institute
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT02853331
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4500)
DOI
10.1200/JCO.2019.37.15_suppl.4500
Abstract #
4500
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2019 Genitourinary Cancers Symposium
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase III KEYNOTE-426 study.
Speaker: Thomas Powles, MD, PhD, FCRP
Videos & Slides
2022 ASCO Annual Meeting
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Analysis of progression after first subsequent therapy in KEYNOTE-426.
Speaker: Thomas Powles, MD, PhD, FCRP
Videos & Slides
2021 ASCO Annual Meeting
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426
Speaker: Brian I. Rini, FASCO, MD
Videos & Slides
2012 Genitourinary Cancers Symposium
Phase III AXIS trial for second-line metastatic renal cell carcinoma (mRCC): Effect of prior first-line treatment duration and axitinib dose titration on axitinib efficacy.
Speaker: Brian I. Rini, MD